Kostroma

Researchers are studying the safety, tolerability, how the body processes, immune response, and early anti-tumor effects of trastuzumab deruxtecan T-DXd alone or combined with chemotherapy andor immunotherapy. This study focuses on adults with HER2-expressing advanced or metastatic gastric, gastroesophageal junction GEJ, and esophageal adenocarcinoma who have either not been treated before for advanced disease or have progressed after prior trastuzumab treatment. The trial aims to find manageable safety profiles and preliminary evidence of anti-tumor activity to support further testing.